vs
Side-by-side financial comparison of Avidbank Holdings, Inc. (AVBH) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $28.0M, roughly 1.2× Avidbank Holdings, Inc.). Avidbank Holdings, Inc. runs the higher net margin — 32.3% vs -299.9%, a 332.1% gap on every dollar of revenue.
Avidbank Holdings, Inc. is a U.S.-based financial holding company operating through its subsidiary AvidBank. It offers commercial banking products and services primarily to small and medium-sized enterprises, business owners, and high-net-worth individuals across California, including commercial loans, deposit accounts, cash management, and customized financing solutions for sectors like manufacturing, technology, real estate and professional services.
AVBH vs KPTI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.0M | $34.1M |
| Net Profit | $9.0M | $-102.2M |
| Gross Margin | — | — |
| Operating Margin | — | -52.4% |
| Net Margin | 32.3% | -299.9% |
| Revenue YoY | — | 11.6% |
| Net Profit YoY | 65.9% | -232.0% |
| EPS (diluted) | $0.84 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $28.0M | — | ||
| Q4 25 | $26.8M | $34.1M | ||
| Q3 25 | $48.0K | $44.0M | ||
| Q2 25 | $21.8M | $37.9M | ||
| Q1 25 | — | $30.0M | ||
| Q4 24 | — | $30.5M | ||
| Q3 24 | — | $38.8M | ||
| Q2 24 | — | $42.8M |
| Q1 26 | $9.0M | — | ||
| Q4 25 | $6.9M | $-102.2M | ||
| Q3 25 | $-37.7M | $-33.1M | ||
| Q2 25 | $5.8M | $-37.3M | ||
| Q1 25 | — | $-23.5M | ||
| Q4 24 | — | $-30.8M | ||
| Q3 24 | — | $-32.1M | ||
| Q2 24 | — | $23.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | -52.4% | ||
| Q3 25 | -110491.7% | -34.6% | ||
| Q2 25 | 38.0% | -64.3% | ||
| Q1 25 | — | -110.8% | ||
| Q4 24 | — | -102.4% | ||
| Q3 24 | — | -67.8% | ||
| Q2 24 | — | -65.7% |
| Q1 26 | 32.3% | — | ||
| Q4 25 | 25.9% | -299.9% | ||
| Q3 25 | -78614.6% | -75.2% | ||
| Q2 25 | 26.6% | -98.2% | ||
| Q1 25 | — | -78.2% | ||
| Q4 24 | — | -100.8% | ||
| Q3 24 | — | -82.7% | ||
| Q2 24 | — | 55.6% |
| Q1 26 | $0.84 | — | ||
| Q4 25 | $0.65 | $-7.02 | ||
| Q3 25 | $-4.12 | $-3.82 | ||
| Q2 25 | $0.75 | $-4.32 | ||
| Q1 25 | — | $-2.77 | ||
| Q4 24 | — | $-2.33 | ||
| Q3 24 | — | $-3.85 | ||
| Q2 24 | — | $-2.97 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $60.5M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $287.2M | $-292.9M |
| Total Assets | $2.5B | $108.4M |
| Debt / EquityLower = less leverage | 0.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $60.5M | ||
| Q3 25 | — | $37.7M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | — | $38.8M | ||
| Q4 24 | — | $62.5M | ||
| Q3 24 | — | $72.8M | ||
| Q2 24 | — | $84.8M |
| Q1 26 | $55.0M | — | ||
| Q4 25 | $60.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $287.2M | — | ||
| Q4 25 | $278.4M | $-292.9M | ||
| Q3 25 | $273.1M | $-269.3M | ||
| Q2 25 | $204.4M | $-238.9M | ||
| Q1 25 | — | $-205.9M | ||
| Q4 24 | — | $-186.0M | ||
| Q3 24 | — | $-159.6M | ||
| Q2 24 | — | $-132.1M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | $108.4M | ||
| Q3 25 | $2.4B | $96.2M | ||
| Q2 25 | $2.4B | $104.9M | ||
| Q1 25 | — | $127.7M | ||
| Q4 24 | — | $164.4M | ||
| Q3 24 | — | $189.5M | ||
| Q2 24 | — | $214.0M |
| Q1 26 | 0.19× | — | ||
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-11.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-11.8M | ||
| Q3 25 | $12.4M | $-5.9M | ||
| Q2 25 | $10.7M | $-18.7M | ||
| Q1 25 | — | $-39.0M | ||
| Q4 24 | — | $-25.8M | ||
| Q3 24 | — | $-19.5M | ||
| Q2 24 | — | $-38.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $12.4M | — | ||
| Q2 25 | $10.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-25.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 25783.3% | — | ||
| Q2 25 | 48.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -84.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | 72.9% | 0.0% | ||
| Q2 25 | 0.3% | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.84× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.62× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVBH
| Net Interest Income | $26.5M | 95% |
| Noninterest Income | $1.5M | 5% |
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
